Feltgen, Nicolas

[["dc.bibliographiccitation.firstpage","561"],["dc.bibliographiccitation.issue","05"],["dc.bibliographiccitation.journal","Klinische Monatsblätter für Augenheilkunde"],["dc.bibliographiccitation.lastpage","568"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Al-Nawaiseh, Sami"],["dc.contributor.author","Chronopoulos, Argyrios"],["dc.date.accessioned","2021-07-05T14:57:27Z"],["dc.date.available","2021-07-05T14:57:27Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Background The progression of the COVID-19 pandemic has caused significant changes in the environment for outpatient and inpatient care in ophthalmology, with limitations on access to medical care but also new observations and challenges. We now describe major developments in recent months and provide an outlook on the expected consequences. Methods PubMed literature search, clinical survey. Results To date, the course of the COVID-19 pandemic has been characterised by several new but overall rare ocular manifestations, the ophthalmological shared management of COVID-19 patients on intensive care units, and a significant decrease in case numbers, associated with an increase in case severity and relative proportion of emergencies, as a result of delayed presentation of patients and reduced treatment adherence. With the introduction of hygiene measures and infection control procedures, ophthalmic patient care was maintained – including emergencies and urgent treatments. Due to the extensive postponement of elective surgeries, scarce therapeutic and health care professional resources, and the prioritisation of critically ill patients from other specialties, there is a reasonable likelihood that urgent treatments will be delayed as infection rates rise. Conclusion Outpatient and inpatient care in ophthalmology during the COVID-19 pandemic is primarily accompanied by additional organisational or medical challenges and a decline in case volume. Although to date emergency and urgent ophthalmic treatments have been maintained, long-term persistence of pandemic conditions will require additional strategies to provide continuation of ophthalmic care at the required level."],["dc.description.abstract","Zusammenfassung Hintergrund Mit fortschreitender Dauer hat die COVID-19-Pandemie zu einer deutlichen Veränderung der Rahmenbedingungen für die ambulante und stationäre Augenheilkunde mit Einschränkungen bei der medizinischen Versorgung, aber auch neuen Beobachtungen und Herausforderungen geführt. Der vorliegende Beitrag beschreibt wesentliche Entwicklungen der vergangenen Monate und gibt einen Ausblick auf die zu erwartenden Folgen. Methoden Literaturrecherche über PubMed, klinische Beobachtungen. Ergebnisse Neben neuen, aber insgesamt seltenen okulären Manifestationen sowie der augenärztlichen Mitbetreuung intensivmedizinisch behandelter COVID-19-Patienten wurde im bisherigen Verlauf der COVID-19-Pandemie weltweit vor allem ein Rückgang der Fallzahlen bei gleichzeitigem Anstieg der Fallschwere und des relativen Anteils an Notfällen beobachtet, was u. a. auf eine verzögerte Vorstellung der Patienten und eine niedrigere Therapieadhärenz zurückzuführen ist. Mit der Einführung von Hygienemaßnahmen und Abläufen für den Infektionsschutz konnten sowohl die Notfallversorgung als auch die Durchführung dringlicher Behandlungen aufrechterhalten werden. Aufgrund der umfangreichen Verschiebung elektiver Operationen, knapper personeller und operativer Ressourcen sowie der Priorisierung der Behandlung vitaler Indikationen anderer Fachrichtungen muss bei steigenden Infektionszahlen zunehmend auch mit einer Verzögerung dringlicher Eingriffe gerechnet werden. Schlussfolgerung Die ambulante und stationäre Augenheilkunde während der COVID-19-Pandemie wird vor allem durch zusätzliche organisatorische und medizinische Herausforderungen sowie einen Rückgang der Fallzahlen begleitet. Obwohl ophthalmologische Notfallbehandlungen und dringliche Therapien bis dato gewährleistet werden konnten, würde ein langfristiges Andauern der Pandemiebedingungen zusätzliche Strategien erfordern, um eine Patientenversorgung auf dem erforderlichen Niveau weiterhin zu gewährleisten."],["dc.description.abstract","Abstract Background The progression of the COVID-19 pandemic has caused significant changes in the environment for outpatient and inpatient care in ophthalmology, with limitations on access to medical care but also new observations and challenges. We now describe major developments in recent months and provide an outlook on the expected consequences. Methods PubMed literature search, clinical survey. Results To date, the course of the COVID-19 pandemic has been characterised by several new but overall rare ocular manifestations, the ophthalmological shared management of COVID-19 patients on intensive care units, and a significant decrease in case numbers, associated with an increase in case severity and relative proportion of emergencies, as a result of delayed presentation of patients and reduced treatment adherence. With the introduction of hygiene measures and infection control procedures, ophthalmic patient care was maintained – including emergencies and urgent treatments. Due to the extensive postponement of elective surgeries, scarce therapeutic and health care professional resources, and the prioritisation of critically ill patients from other specialties, there is a reasonable likelihood that urgent treatments will be delayed as infection rates rise. Conclusion Outpatient and inpatient care in ophthalmology during the COVID-19 pandemic is primarily accompanied by additional organisational or medical challenges and a decline in case volume. Although to date emergency and urgent ophthalmic treatments have been maintained, long-term persistence of pandemic conditions will require additional strategies to provide continuation of ophthalmic care at the required level."],["dc.description.abstract","Zusammenfassung Hintergrund Mit fortschreitender Dauer hat die COVID-19-Pandemie zu einer deutlichen Veränderung der Rahmenbedingungen für die ambulante und stationäre Augenheilkunde mit Einschränkungen bei der medizinischen Versorgung, aber auch neuen Beobachtungen und Herausforderungen geführt. Der vorliegende Beitrag beschreibt wesentliche Entwicklungen der vergangenen Monate und gibt einen Ausblick auf die zu erwartenden Folgen. Methoden Literaturrecherche über PubMed, klinische Beobachtungen. Ergebnisse Neben neuen, aber insgesamt seltenen okulären Manifestationen sowie der augenärztlichen Mitbetreuung intensivmedizinisch behandelter COVID-19-Patienten wurde im bisherigen Verlauf der COVID-19-Pandemie weltweit vor allem ein Rückgang der Fallzahlen bei gleichzeitigem Anstieg der Fallschwere und des relativen Anteils an Notfällen beobachtet, was u. a. auf eine verzögerte Vorstellung der Patienten und eine niedrigere Therapieadhärenz zurückzuführen ist. Mit der Einführung von Hygienemaßnahmen und Abläufen für den Infektionsschutz konnten sowohl die Notfallversorgung als auch die Durchführung dringlicher Behandlungen aufrechterhalten werden. Aufgrund der umfangreichen Verschiebung elektiver Operationen, knapper personeller und operativer Ressourcen sowie der Priorisierung der Behandlung vitaler Indikationen anderer Fachrichtungen muss bei steigenden Infektionszahlen zunehmend auch mit einer Verzögerung dringlicher Eingriffe gerechnet werden. Schlussfolgerung Die ambulante und stationäre Augenheilkunde während der COVID-19-Pandemie wird vor allem durch zusätzliche organisatorische und medizinische Herausforderungen sowie einen Rückgang der Fallzahlen begleitet. Obwohl ophthalmologische Notfallbehandlungen und dringliche Therapien bis dato gewährleistet werden konnten, würde ein langfristiges Andauern der Pandemiebedingungen zusätzliche Strategien erfordern, um eine Patientenversorgung auf dem erforderlichen Niveau weiterhin zu gewährleisten."],["dc.identifier.doi","10.1055/a-1487-1742"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87646"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","1439-3999"],["dc.relation.issn","0023-2165"],["dc.title","Ophthalmic Outpatient and Inpatient Care Under Pandemic Conditions: Hygiene, Triage and New Challenges"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E29"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","E37"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Mirshahi, Alireza"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Lorenz, Katrin"],["dc.contributor.author","Korb, Christina"],["dc.contributor.author","Junker, Bernd"],["dc.contributor.author","Schaefer, Caroline"],["dc.contributor.author","Zwiener, Isabella"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.date.accessioned","2018-11-07T10:01:40Z"],["dc.date.available","2018-11-07T10:01:40Z"],["dc.date.issued","2015"],["dc.description.abstract","Purpose: To compare standard-of-care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branch retinal vein occlusion. Methods: Prospective, randomized, multicentre clinical trial. Thirty patients with a best-corrected visual acuity (BCVA) between 20/320 and 20/40 were randomized 1:1:1 to receive grid laser or three monthly injections of 0.5 mg IVR or both followed by 3 months of observation. Results: Mean change from baseline BCVA at month 6 was +2 letters [laser; 0.04 logMAR, 95% confidence interval (-0.17; 0.25)], +17 letters [IVR; 0.34 (0.19; 0.5)] and +6 letters [combination; 0.12 (0.01; 0.24)] (IVR versus laser p = 0.02 and IVR versus combination p = 0.02). At month 3, mean improvement in central retinal thickness (CRT) was 90.6 mu m (laser) (-18.65; 199.8), 379.5 mu m (IVR) (204.2; -554.8), and 248 mu m (167.2; -328.8) (combination) (IVR versus laser p = 0.005, laser versus combination p = 0.02). During the observation period, CRT improved in laser [37.6 mu m (-66.82; 142.0)], but deteriorated in IVR [-142.4 mu m (-247.6; -37.16)] and combination [-171.7 mu m (-250.4; -92.96)] (laser versus IVR p = 0.01, laser versus combination p = 0.002) indicating recurrent oedema. Less laser retreatments (at 8 weeks) were required in combination group (2/10) than grid group (7/10). Conclusion: Six-month results suggest that ranibizumab may be superior to grid laser in improving visual acuity. Grid combined with IVR neither enhanced functional and morphological improvement of IVR nor did it prevent or prolong recurrence of oedema. In IVR groups, CRT increased slowly after stopping injections, whereas improvement in visual acuity was sustained, indicating that morphological changes occur prior to functional impairment."],["dc.identifier.doi","10.1111/aos.12488"],["dc.identifier.isi","000348500500005"],["dc.identifier.pmid","25042729"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38071"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1755-3768"],["dc.relation.issn","1755-375X"],["dc.title","Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2021-06-01T10:49:09Z"],["dc.date.available","2021-06-01T10:49:09Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00347-021-01364-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86186"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","The urgency of surgical treatment for rhegmatogenous retinal detachment"],["dc.title.translated","Dringlichkeit der operativen Versorgung bei der rissbedingten Netzhautablösung"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1121"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Die Ophthalmologie"],["dc.bibliographiccitation.lastpage","1128"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2022-12-01T08:31:53Z"],["dc.date.available","2022-12-01T08:31:53Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1007/s00347-022-01750-z"],["dc.identifier.pii","1750"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118296"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2731-7218"],["dc.relation.issn","2731-720X"],["dc.rights.uri","https://www.springer.com/tdm"],["dc.title","Ischämie und Lasertherapie bei retinalen venösen Verschlüssen"],["dc.title.translated","Ischemia and laser photocoagulation in retinal vein occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","604"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Current Eye Research"],["dc.bibliographiccitation.lastpage","614"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Vögeler, Jessica"],["dc.contributor.author","Priglinger, Siegfried"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Rehak, Matus"],["dc.date.accessioned","2021-04-14T08:26:42Z"],["dc.date.available","2021-04-14T08:26:42Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1080/02713683.2019.1679839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82046"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1460-2202"],["dc.relation.issn","0271-3683"],["dc.title","Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e933"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e941"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Rose, Uwe"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/aos.13770"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76197"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmologica"],["dc.bibliographiccitation.volume","232"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Pankaj, Puri"],["dc.contributor.author","Berk, Huesnue"],["dc.contributor.author","Knorr, Thomas"],["dc.date.accessioned","2018-11-07T09:45:40Z"],["dc.date.available","2018-11-07T09:45:40Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000345450600236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34673"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0267"],["dc.relation.issn","0030-3755"],["dc.title","Efficacy and Safety of 0.5 mg Ranibizumab Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Central Retinal Vein Occlusion Over 6 Months: The COMRADE-C Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmologica"],["dc.bibliographiccitation.volume","232"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Lang, Gabrielle"],["dc.contributor.author","Taylor, Simon"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Knorr, Thomas"],["dc.date.accessioned","2018-11-07T09:45:39Z"],["dc.date.available","2018-11-07T09:45:39Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000345450600235"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34672"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0267"],["dc.relation.issn","0030-3755"],["dc.title","Efficacy and Safety of 0.5 mg Ranibizumab Administered as Intravitreal Injections PRN Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Branch Retinal Vein Occlusion Over 6 Months: The COMRADE-B Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","858"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","865"],["dc.bibliographiccitation.volume","117"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2021-04-14T08:24:48Z"],["dc.date.available","2021-04-14T08:24:48Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00347-020-01191-6"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81427"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","Dringlichkeit der operativen Versorgung bei der rissbedingten Netzhautablösung"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","258"],["dc.bibliographiccitation.journal","American Journal of Ophthalmology"],["dc.bibliographiccitation.lastpage","267"],["dc.bibliographiccitation.volume","169"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Weiss, Claudia"],["dc.contributor.author","Paulus, Eva-Maria"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Puri, Pankaj"],["dc.contributor.author","Berk, Husnu"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Wiedemann, Peter"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.date.accessioned","2018-11-07T10:09:02Z"],["dc.date.available","2018-11-07T10:09:02Z"],["dc.date.issued","2016"],["dc.description.abstract","PURPOSE: To compare the efficacy and safety of the European labels of ranibizumab 0.5 mg vs dexamethasone 0.7 mg in patients with macular edema secondary to central retinal vein occlusion (CRVO). DESIGN: Phase IIIb, multicenter, double-masked, randomized clinical trial. METHODS: Patients were randomized (1:1) to receive either monthly ranibizumab followed by pro re nata (PRN) treatment (n = 124) or 1 sustained-release dexamethasone implant followed by PRN sham injections (n = 119). Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to month 1 through month 6, mean change in BCVA, and adverse events (AEs). RESULTS: Of 243 patients, 185 (76.1%) completed the study. No difference was observed in BCVA between ranibizumab and dexamethasone at months 1 and 2. From month 3 to month 6, there was significant difference in BCVA gains in favor of ranibizumab. At month 6, mean average BCVA gain was significantly higher with ranibizumab than with dexamethasone (12.86 vs 2.96 letters; difference 9.91 letters, 95% confidence interval [6.51-43.30]; P < .0001). Mean injection number of ranibizumab was 4.52. Ocular AEs were reported in more patients in the dexamethasone than in the ranibizumab group (86.6% vs 55.6%). CONCLUSIONS: Using the European labels, similar efficacy was observed for ranibizumab and dexamethasone at months 1 and 2. However, ranibizumab maintained its efficacy throughout the study, whereas dexamethasone declined from month 3 onward. The main limitation of the study was that dexamethasone patients received only a single treatment during the 6-month study. In clinical practice, dexamethasone retreatment may be required earlier than 6 months. Safety findings were similar to those previously reported. (C) 2016 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","NOVARTIS PHARMA GMBH, GERMANY"],["dc.identifier.doi","10.1016/j.ajo.2016.04.020"],["dc.identifier.isi","000383637300027"],["dc.identifier.pmid","27163237"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39587"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1879-1891"],["dc.relation.issn","0002-9394"],["dc.title","Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]